← Browse by Condition
Medical Condition
metastatic cancer
Total Trials
20
Recruiting Now
20
Trial Phases
Phase 1, Phase 3, Phase 1, Phase 2
NCT06533059 Phase 1
Recruiting
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Enrollment
110 pts
Location
United States, Austr...
Sponsor
Alterome Therapeutics, Inc.
NCT07269080 Phase 1
Recruiting
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Enrollment
28 pts
Location
United States
Sponsor
University of Illinois at Chic...
NCT05831579
Recruiting
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Enrollment
24 pts
Location
United States
Sponsor
Washington University School o...
NCT05825456
Recruiting
Metastatic Pathologic Fractures, Short Term Results
Enrollment
200 pts
Location
Turkey (Türkiye)
Sponsor
Ankara University
NCT05349227
Recruiting
Comprehensive Outcomes for After Cancer Health
Enrollment
625 pts
Location
United States
Sponsor
Pack Health
NCT07011862
Recruiting
COBRA: Cancer, Older Adults, Balance and Resistance Activities
Enrollment
38 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06346197 Phase 3
Recruiting
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Enrollment
132 pts
Location
France
Sponsor
Centre Leon Berard
NCT05076760 Phase 1
Recruiting
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Enrollment
40 pts
Location
United States
Sponsor
Memgen, Inc.
NCT06081517
Recruiting
Evaluating Disparities in Precision Oncology
Enrollment
10,600 pts
Location
United States
Sponsor
Indiana University
NCT05394103 Phase 1, Phase 2
Recruiting
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Enrollment
130 pts
Location
United States, South...
Sponsor
Qurient Co., Ltd.
NCT06067503 Phase 2
Recruiting
Biomarkers to Detect Endocrine Therapy Resistance
Enrollment
8 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
NCT05065736 EARLY_Phase 1
Recruiting
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Enrollment
4 pts
Location
United States
Sponsor
Roberto Vargas
NCT06230666
Recruiting
Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases
Enrollment
62 pts
Location
Switzerland
Sponsor
Matthias Guckenberger
NCT05610501
Recruiting
Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.
Enrollment
200 pts
Location
Belgium, Czechia, It...
Sponsor
Universitaire Ziekenhuizen KU ...
NCT05283044
Recruiting
Implementing Precision Medicine in cOmmunity HospiTALs
Enrollment
10,000 pts
Location
France, French Polyn...
Sponsor
Gustave Roussy, Cancer Campus,...
NCT05260671 Phase 2
Recruiting
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Enrollment
48 pts
Location
China
Sponsor
Eye & ENT Hospital of Fudan Un...
NCT06121700 Phase 2
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Enrollment
55 pts
Location
China
Sponsor
Fudan University
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc
NCT06524570 Phase 1
Recruiting
Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy
Enrollment
24 pts
Location
Netherlands
Sponsor
UMC Utrecht
NCT06154291 Phase 1, Phase 2
Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
Enrollment
255 pts
Location
Belgium, France
Sponsor
Xenothera SAS